

CF Foundation Specimen Banking			
Study Long Title	A Multicenter Longitudinal Study of CFTR-dependent Disease Profiling in Cystic Fibrosis		
Short Name	PROSPECT Prospective Biomarkers Study		
Specimens Currently Available to Other Researchers	Not Yet		
Current Study Status	Completed		
Study Timeline Metrics			
	Planned	Actual (Sponsor)	
Begin Enrollment	03/15/2015	03/25/2015	
Complete Enrollment	03/31/2017		
Study Complete	03/31/2018		
Number of Patients Planned	260		
General Study Information			
Study Type	Observational		
Intervention Type			
Control Type			
Blinded	No		
Randomized	No		
Duration of Subject Participation	15 Months		
Endpoints Evaluated	Sweat Chloride, Sputum Inflammatory Mediators, LRT Microbiology, MCC, LCI, Other PRO		
Trial Specific Link on ClinicalTrials.gov	https://clinicaltrials.gov/ct2/show/NCT02477319		
Primary Manuscript Link			
Primary Manuscript Citation			
Eligibility Criteria			
Age	>= 6 Years		
FEV1	No FEV1 requirement		
P. aeruginosa status	Not Applicable		
B. cepacia status	Not Applicable		
Other Primary Eligibility Requirements	Participants in Part B are required to have two copies of the F508del CFTR Mutation and to be prescribed Orkambi. The initial study visit must occur before the participant begins taking Orkambi.		
Biorepository Specimen Information			
General Specimen Information			
Part A and B:			
Human Nasal Epithelial (HNE) Cells will be collected from subjects who signed the informed consent indicating willingness to participate in the OPTIONAL genomic component of the study. Nasal cells are only to be collected one time and the timing of collection is not visit specific. Buffy Coat (WBC) samples will be obtained only from subjects who signed the informed consent indicating willingness to participate in the OPTIONAL genomic component of the study.			
Part B :			
Visit 4 is the baseline for Part B of the study (only F508Del subjects are eligible for Part B). Day 1 is designated as the start of treatment with lumacaftor/ivacaftor. Visit 5 should occur 30 days after first dose of lumacaftor/ivacaftor (Day 1).			
Visit #	Time from Baseline	Specimens Collected	
1	+0 Days	serum, EDTA plasma, buffy coat, sputum, urine	
2	+14 Days	serum, EDTA plasma, buffy coat, sputum, stool, urine	
3	+90 Days	serum, EDTA plasma, buffy coat, stool, urine	
4	+0 Days	serum, EDTA plasma, buffy coat, sputum, urine	

5	+60	serum, EDTA plasma, buffy coat, sputum, urine
6	+90	serum, EDTA plasma, buffy coat, urine
7	+180 Days	serum, EDTA plasma, buffy coat, sputum, urine
8	+360 Days	serum, EDTA plasma, buffy coat, sputum, urine